Evidence map›Paper›PMID 27765808›Full record

ArticleThe international journal of neuropsychopharmacology2017

Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine.

Chao Dong, Ji-Chun Zhang, Wei Yao, Qian Ren, Min Ma, Chun Yang, Shigeyuki Chaki, Kenji Hashimoto

Open access · goldAbstract readComparative Study
In one paragraph

Article in The international journal of neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 116 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. TrkB receptor interacts with mGluScience advances · 2024
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Combined Administration of (Pharmaceuticals (Basel, Switzerland) · 2022
    Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chao DongDivision of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan; Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Ji-Chun ZhangDivision of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan; Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Wei YaoDivision of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan; Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Qian RenDivision of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan; Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Min MaDivision of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan; Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Chun YangDivision of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan; Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Shigeyuki ChakiDivision of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan; Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Kenji HashimotoDivision of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan; Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Center for Forensic Mental Health, Chiba University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Similar to the N-methyl-D-aspartate receptor antagonist ketamine, the metabotropic glutamate 2/3 receptor antagonist, MGS0039, shows antidepressant effects. However, there are no reports comparing these 2 compounds in the social defeat stress model of depression. Methods: We examined the effects of MGS0039 (1 mg/kg) and ketamine (10 mg/kg) on depression-like behavior in susceptible mice after repeated social defeat stress. Protein levels of brain-derived neurotrophic factor, TrkB, phospho-TrkB, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (GluA1), postsynaptic density protein 95, and dendritic spine density in selected brain regions were measured. Results: In the tail suspension and forced swimming tests, both MGS0039 and ketamine significantly attenuated the increased immobility time observed in susceptible mice, compared with vehicle-treated animals, 1 or 2 days after a single dose of drug. In the sucrose preference test, both compounds significantly improved the reduced preference typically seen in susceptible mice at 3 to 7 days after a single dose of drug. Western-blot analyses showed that similar to ketamine, MGS0039 significantly attenuated the reduced brain-derived neurotrophic factor, phospho-TrkB/TrkB ratio, GluA1 and postsynaptic density protein 95 seen in the prefrontal cortex, dentate gyrus, and CA3 of the hippocampus from susceptible mice, 8 days after a single dose. Again, in a similar manner to ketamine, MGS0039 significantly attenuated the reduction of spine density in the prelimbic regions of the medial prefrontal cortex, dentate gyrus, and CA3 of the hippocampus, but not infralimbic regions of the medial prefrontal cortex and CA1, in susceptible mice 8 days after a single dose. In contrast, neither drug elicited an effect on altered brain-derived neurotrophic factor-TrkB signaling, GluA1, and postsynaptic density protein 95 levels and did not increase spine density observed in the nucleus accumbens of susceptible mice. Conclusions: Similar to ketamine, MGS0039 shows rapid and sustained antidepressant effects in the social defeat stress model. Long-lasting synaptogenesis in the prelimbic regions of medial prefrontal cortex, dentate gyrus, and CA3 might be implicated in this sustained antidepressant effect.

Indexed as

AnimalsAntidepressive AgentsBehavior, AnimalBrainBrain-Derived Neurotrophic FactorBridged Bicyclo CompoundsDendritic SpinesDicarboxylic AcidsDisks Large Homolog 4 ProteinFood PreferencesImmobility Response, TonicKetamineMaleMiceProtein KinasesReceptors, Metabotropic Glutamate2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo(3.1.0)hexane-2,6-dicarboxylic acidAntidepressive AgentsBrain-Derived Neurotrophic FactorBridged Bicyclo CompoundsDicarboxylic AcidsDisks Large Homolog 4 ProteinDlg4 protein, mouseKetaminemetabotropic glutamate receptor 2Protein KinasesReceptors, Metabotropic Glutamatetropomyosin kinaseantidepressantBDNF-TrkB signalingketaminemetabotropic glutamate 2/3 (mGlu2/3) receptor antagonistsocial defeat stress modelsynaptogenesis

Identifiers

PMID27765808
PMCPMC5408970
OpenAlexW2528777034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.